Table 2.
Elixhauser comorbidities and other comorbid conditions and medication use among Covid-19 -related hospitalizations
|
CU N = 13,750 |
No CU N = 1,684,810 |
|
|---|---|---|
| Mean Percent (Std. err.) | Mean Percent (Std. err.) | |
| Congestive Heart Failure | 11.02% (0.59)** | 17.61% (0.13)** |
| Cardiac Arrhythmias | 13.93% (0.70)** | 24.69% (0.14)** |
| Valvular Disease | 2.25% (0.28)** | 3.99% (0.05)** |
| Pulmonary Circulation Disorders | 3.78% (0.66)** | 5.27% (1.28)** |
| Peripheral Vascular Disorders | 2.87% (1.14)** | 4.79% (0.48)** |
| Paralysis | 1.78% (0.25)** | 1.33% (0.02)** |
| Other Neurological Disorders | 13.93% (2.96)** | 17.15% (4.19)** |
| Uncomplicated Hypertension | 37.05% (8.55)** | 55.14% (13.65)** |
| Complicated Hypertension | 14.69% (0.71)** | 27.10% (0.16)** |
| Chronic Pulmonary Disease | 22.33% (0.83) | 22.11% (0.14) |
| Uncomplicated Diabetes | 8.87% (0.55)** | 14.80% (0.10)** |
| Complicated Diabetes | 15.24% (0.70)** | 26.27% (0.14)** |
| Hypothyroidism | 4.07% (0.37)** | 13.23% (0.10)** |
| Renal Failure | 11.09% (0.61)** | 21.05% (0.13)** |
| Liver Disease | 8.51% (0.53)** | 5.42% (0.06)** |
| Peptic Ulcer Disease without Bleeding | 0.62% (0.15)** | 0.31% (0.01)** |
| AIDS/HIV | 1.31% (0.26)** | 0.26% (0.01)** |
| Lymphoma | 0.55% (0.14) | 0.81% (0.02) |
| Metastatic Cancer | 0.87% (0.18) | 1.12% (0.02) |
| Solid Tumor Without Metastasis | 1.75% (0.25)** | 2.48% (0.60)** |
| Rheumatoid Arthritis/Collagen Vascular disorders | 1.67% (0.23)** | 2.94% (0.04)** |
| Coagulopathy | 8.62% (0.55)** | 12.14% (0.18)** |
| Obesity | 20.51% (0.81)** | 25.56 (0.22)** |
| Severe Obesity | 10.98% (0.63)** | 13.53% (0.11)** |
| Obesity with Complicated Diabetes | 2.27% (0.05)** | 5.61% (0.05)** |
| Weight Loss | 5.31% (0.46)** | 7.85% (0.13)** |
| Fluid & Electrolyte Disorders | 40.11% (9.27)** | 50.36% (12.43)** |
| Blood Loss Anemia | 0.29% (0.10)** | 0.45% (0.01)** |
| Deficiency Anemia | 4.04% (0.40) | 3.86% (0.05) |
| Alcohol Abuse | 18.22% (0.77)** | 2.53% (0.04)** |
| Drug Abuse | -- | 1.79% (0.04) |
| Psychoses | 14.65% (0.87)** | 2.47% (0.05)** |
| Depression | 20.40% (0.82)** | 11.62% (0.12)** |
| Remdesivir Administration | 9.13% (0.58)** | 22.91% (0.30)** |
| Baricitinib Administration | 0.001 (8.03e-06)** | 0.01 (0.002)** |
| Long-term Steroid Use | 1.24% (0.21)** | 1.74% (0.04)** |
| Long-term Anticoagulation | 4.55% (0.40)** | 9.56% (0.10)** |
| Long-term (Current) Drug Therapy | 18.07% (0.88) | 19.70% (0.46) |
| Long-Term NSAID | 1.16% (0.21) | 0.94% (0.03) |
| Long-Term Aspirin Use | 7.49% (0.51)** | 14.45% (0.19)** |
| History of Bariatric Surgery | 0.52% (0.14) | 0.73% (0.02) |
| Septic Shock | 3.05% (0.33)** | 7.33% (0.09)** |
| Cardiogenic Shock | 0.62% (0.15) | 0.63% (0.02) |
| Active Cannabis Abuse Disorder | 92.07% (0.38) | -- |
| Active Cannabis Dependence Disorder | 5.85% (0.37) | -- |
| Cannabis Abuse Remission | 1.71% (0.26) | -- |
| Cannabis Dependence Remission | 0.36% (0.12) | -- |
| APDRG 3&4 | 85.42% (0.72)** | 94.29% (0.08)** |
| Elixhauser Sum ≥ 4 | 51.56% (1.05) | 50.35% (0.23) |
| Covid-19 Primary Diagnosis | 36.64% (1.02)** | 60.37% (0.31)** |
| Covid-19 Diagnosis after Admission | 63.36% (1.02)** | 39.63% (0.31)** |
**P less than or equal to 0.05 on χ2 analysis